EZH2 and hepatocellular carcinoma: While previous studies demonstrate that EZH2 inhibitor GSK126 enhances transcription of NK cell ligands to promote natural killer cell-mediated HCC cell death, additional studies ought to be conducted to validate the benefit of EZH2 inhibitors in conjunction with ICIs (118).